Transcend: девять шагов на пути к вечной жизни
Шрифт:
3. Lagergvist B., James S., Stenestrand U., Lindback M., Nilsson T., Wallentin L. (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden // NEJM 356 (10): 1009–1019.
4. Enos W. F, Holmes R. H, Beyer J (1953) Coronary disease among United States soldiers killed in action in Korea // JAMA 152: 1090–1093.
5. The Society for Women’s Health Research, “What really claims women’s lives?” womenshealthresearch.org/site/PageServer?pagename=hs_whatclaims.
6. Becker D., Gordon R., Morris P., Yorko J., Gordon J., Li M., Iqbal N. (2008) Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trail // Mayo Clin Proc 83: 758–764.
7. Lu Z., Kou W., Du B., Wu Y., Zhao S., Brusco O., Morgan J., Capuzzi D. (2008) Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction // Amer J. of Card 12 (101): 1689–1693.
8. Gouni-Berthold J., Berthold H. (2002) Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent // Amer Heart J. 143 (2): 356–365.
9. Morike E. M. (1996) Vitamin E treatment of patients with coronary disease // Deutsch Med Wochenschr May, 121 (21): A9.
10. Brook J. G., Linn S., Aviram M. (1986) Phosphatidlylinositol raises HDL cholesterol levels in humans // Biochem Med Metabol Biol (35): 31–39.
11. Katsuyuki M., Daviglus M. L., Dyer A. R., Kiang L., Garside D. B., Stamler J., Greenland P. (2001) Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: The Chicago Heart Association detection project in industry // Arch Intern Med 161: 1501–1509.
12. Bolotin H. H. (2007) DXA in vivo BMD methodology: An erroneous and misleading research and clinical gauge of bone mineral status, bone fragility, and bone remodelling // Bone 41 (1): 138–154.
1. Drossman D. A., Li Z., Andruzzi E., Temple R. D., Talley N. J., Thompson W. G., Whitehead W. E., Janssens J., Funch-Jensen P., Corazziari E. et al. (1993) U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodermography, and health impact // Digestive Disease Science 38 (9): 1569–1580.
2. Krasinski S. D., Russell R. M., Samloff I. M., Jacob R. A., Dallal G. E., McGandy R. B., Hartz S.C. (1986) Fundic atrophic gastritis in an elderly population // J. Am Geriatr Soc 34 (11): 800–806.
3. Scrimshaw N. S., Murray E. B. (1988) The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance // Am J. Clin Nutr 48 (Suppl 4): 1079–1159.
4. Swagerty D. L. Jr, Walling A. D., Klein R. M. (2002) Lactose intolerance // Amer Fam Physician 65 (9): 1845–1850.
1. Canaris G. J., Manowitz N. R., Mayor G., Ridgeway E. G. (2000) The Colorado thyroid prevalence study // Arch of Int. Med (160): 526–534.
2. Svec F., Porter J. R. (1998) The actions of exogenous dehydroepiandrosterone in experimental animals and humans // Proceedings of the Society for Exp Bio and Med (218): 174–191.
3. Lemon J. A., Boreham D. R., Rollow C. D. (2003) A dietary supplement abolishes age-related cognitive decline in transgenic mice expressing elevated free radical processes // Exp Bio Med. (228): 800–810.
4. Butler R. N., Fossel M., Mitchell H., Heward C. B., Olshansky S. J., Perls T. T., Rothman D. J., Rothman S. M., Warner H. R., West M. D., and Wright W.F. (2002) Is there an anti-aging medicine? // J. of Gerontology Series A: Bio SciMed Sci (57): B333-B3385.
5. Straub R. H., Lehle K., Herfarth H., Weber M., Falk M. W., Preuner J., Scholmerich J. (2002) Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: Role of interleukin-6 and tumour necrosis factor // Eur J. Endo 146: 365–374.
6. National Sleep Foundation, “Epidemic of Daytime Sleepiness Linked to Increased Feelings of Anger, Stress, and Pessimism,” sleepfoundation.org/site/c.huIXKjM0IxF/b.2417359/k.3028/Epidemic_of_Daytime_Sleepiness_Linked_to_ Increased_Feelings_of_Anger_Stress_and_Pessimism.htm.
7. Leger D., Laudon M., Zisapel N. (2004) Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy // Am. J. Med. 116:91–95.
8. The Writing Group for the WHI Investigators (2002) Risks and benefits of estrogen plus progestin in healthy post-menopausal women: Principal results of the Women’s Health Initiative randomized controlled trial // JAMA 288 (3): 321–333.
9. The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial // JAMA 291: 1701–1712.
10. Rossouw J. E., Prentice R. L., Manson J. E., Wu L., Barad D., Barnabei V. M., Ko M., LaCroix A. Z., et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause // JAMA 297: 1465–1477.
11. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. (2005).
12. Rudman D., Drinka P. J., Wilson C. R., Mattson D. E., Scherman F., Cuisinier M. C., Schultz S. (1994) Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men // Clin Endo 40: 653–661.
13. Stephenson K., Price C., Kurdowska A., Neuenschwander P., Stephenson J., Pinson B., Stephenson D., Alfred D., Krupa A., Mahoney D., Zava D., and Bevan M. (2004) Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women // ASH Annual Meeting Abstracts 104: 5318.